SAB4300058
Anti-phospho-ERBB2 (pTyr1221/pTyr1222) antibody produced in rabbit
affinity isolated antibody
别名:
Anti-CD340 antibody produced in rabbit, Anti-HER-2 antibody produced in rabbit, Anti-HER-2/neu antibody produced in rabbit, Anti-HER2 antibody produced in rabbit, Anti-v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro / glioblastoma derived oncogene homolog (avian) antibody produced in rabbit
登录查看公司和协议定价
所有图片(2)
About This Item
分類程式碼代碼:
12352203
NACRES:
NA.41
推荐产品
生物源
rabbit
品質等級
共軛
unconjugated
抗體表格
affinity isolated antibody
抗體產品種類
primary antibodies
無性繁殖
polyclonal
形狀
buffered aqueous solution
分子量
~185 kDa
物種活性
human
濃度
1 mg/mL
技術
indirect immunofluorescence: 1:100-1:200
western blot: 1:500-1:1000
同型
IgG
免疫原序列
(N-L-YP-YP-W)
NCBI登錄號
UniProt登錄號
運輸包裝
wet ice
儲存溫度
−20°C
目標翻譯後修改
phosphorylation (pTyr1221/pTyr1222)
基因資訊
human ... ERBB2(2064)
一般說明
Erb-b2 receptor tyrosine kinase 2 (ErbB2) or human epidermal growth factor receptor 2 (HER2), is encoded by the gene mapped to human chromosome 17. The encoded protein belongs to the family of epidermal growth factors. ErbB2 membrane protein is characterized with a cysteine-rich extracellular ligand-binding domain, a hydrophobic membrane spanning region, and an intracellular tyrosine kinase domain.This protein does not have a ligand, and it either forms heterodimers with other family members or homodimer with itself when expressed at very high levels, to get activated. ErbB2 is expressed at low level in normal tissues, but at high level in breast cancer tissues.
免疫原
Peptide sequence around phosphorylation site of tyrosine1221/1222 (N-L-Y(p)-Y(p) -W), according to the protein ERBB2.
生化/生理作用
Erb-b2 receptor tyrosine kinase 2 (ErbB2) signaling pathway stimulates cell proliferation and survival in the majority of breast cancers. Thus, over expression of this protein causes breast cancer. Heterodimer complex of ErbB2 and phosphatidylinositide 3-kinase (PI3K) is the most potent stimulator of the PI3K/AKT anti-apoptosis pathway. Increased expression of ErbB2 is also observed in ovarian, colorectal, pancreatic, endometrial and gastric cancers. Trastuzumab, an antibody, works by binding to a domain in the external domain of ErbB2. This domain is missing in p95, a truncated form of ErbB2, and hence these cancer cells show resistance to trastuzumab. ErbB2 protein can be used as a prognostic marker and as a therapeutic option for gynecologic cancers.
特點和優勢
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
標靶描述
Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Not activated by EGF, TGF-alpha and amphiregulin.
外觀
Solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品?
试试我们的产品选型工具.
儲存類別代碼
10 - Combustible liquids
水污染物質分類(WGK)
WGK 1
閃點(°F)
Not applicable
閃點(°C)
Not applicable
The role of p95HER2 in trastuzumab resistance in breast cancer.
Ozkavruk Eliyatkin N
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology, 21, 382-389 (2016)
HER2: biology, detection, and clinical implications.
Gutierrez C and Schiff R.
Archives of Pathology & Laboratory Medicine, 135, 55-62 (2011)
HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies.
English DP
Molecular Diagnosis & Therapy, 17, 85-99 (2013)
Toshio Shimizu et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(19), 5032-5040 (2014-08-12)
This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD) for CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 as a 1-hour intravenous (i.v.) infusion for 5 consecutive days every 2 weeks.
Yong Sang Hong et al.
PloS one, 9(10), e109440-e109440 (2014-10-29)
ERBB2-directed therapy is now a routine component of therapy for ERBB2-amplified metastatic gastroesophageal adenocarcinomas. However, there is little knowledge of the mechanisms by which these tumors develop acquired resistance to ERBB2 inhibition. To investigate this question we sought to characterize
Global Trade Item Number
货号 | GTIN |
---|---|
SAB4300058-100UG | 4061832701868 |
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持